IPV-Al SSI

BIOLOGICAL3 trials

Sponsors

Statens Serum Institut

Conditions

Poliomyelitis

Phase 3

Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age

CompletedNCT03025750

Statens Serum InstitutPoliomyelitis

Start: 2017-01-19End: 2017-11-14Updated: 2018-11-14

Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months

CompletedNCT03032419

Statens Serum InstitutPoliomyelitis

Start: 2017-02-06End: 2018-03-12Updated: 2018-11-14

Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months

CompletedNCT03671616

Statens Serum InstitutPoliomyelitis

Start: 2018-05-15End: 2018-10-03Updated: 2018-11-14

Related Papers

Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15-18 months.

2020-04-066 citations

Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age

Vaccine2019-11-0513 citations